πŸ‡ΊπŸ‡Έ FDA
Patent

US 11406713

Xanthine oxidase inhibitor formulations

granted A61KA61K31/197A61K31/198

Quick answer

US patent 11406713 (Xanthine oxidase inhibitor formulations) held by XORTX THERAPEUTICS, INC. expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
XORTX THERAPEUTICS, INC.
Grant date
Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/197, A61K31/198, A61K31/375, A61K31/4188